NS1-Lipoprotein Complex Biomarker for Early Dengue Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for dengue virus infection are inadequate for early detection and prognosis, particularly in rural areas, and lack specificity, leading to challenges in managing severe cases and reducing mortality rates.
Innovation Solution
Development of ELISA-based methods to detect complexes formed between Dengue virus NS1 and plasma lipoprotein particles, specifically high-density lipoprotein (HDL), low-density lipoprotein (LDL), and apolipoproteins A1, B, and E, which serve as novel biomarkers for diagnosis, prognosis, and monitoring of dengue infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (RT-PCR, antibody detection) are used, then viral RNA or antibodies can be detected, but detection timing is delayed and early diagnosis is difficult
Solution Approach 1:
The patent detects NS1 protein and its lipoprotein complexes during the acute phase of dengue infection, before severe complications develop. By identifying the NS1-lipoprotein complex as an early biomarker, diagnosis can be established in the critical early window when intervention is most effective, rather than waiting for antibody production or viral RNA detection which occurs later.
Solution Approach 2:
The patent uses lipoprotein particles (HDL, LDL, VLDL) as intermediary carriers that bind to NS1 protein in the bloodstream. This interaction creates detectable complexes that serve as amplified biomarkers, enhancing the sensitivity and timing of detection compared to detecting NS1 alone or waiting for antibody responses.
2Reliability
If NS1 protein detection is performed, then viral infection can be identified, but lack of specificity makes it difficult to assess disease severity
Solution Approach 1:
The patent segments the NS1 protein detection into different complexes based on their lipoprotein partners (HDL complexes, LDL complexes, VLDL complexes). By analyzing which lipoprotein type NS1 binds to and the ratio of different complexes, the system can differentiate between mild and severe dengue cases, providing prognostic information that simple NS1 detection cannot provide.
Solution Approach 2:
The patent changes the detection parameter from simply measuring NS1 protein concentration to measuring the distribution pattern of NS1 across different lipoprotein complexes. The ratios of HDL:LDL:VLDL complexes serve as diagnostic parameters that correlate with disease severity, enabling both diagnosis and prognosis from a single test.
3Reliability
If comprehensive monitoring of dengue cases is implemented, then disease severity can be tracked, but resource requirements increase particularly in rural areas
Solution Approach 1:
The patent creates a single diagnostic test that serves multiple functions: it detects dengue infection, assesses disease severity, and provides prognostic information all through measurement of NS1-lipoprotein complexes. This multi-functional approach replaces the need for multiple separate tests and complex monitoring protocols, making it particularly suitable for resource-limited settings while maintaining comprehensive monitoring capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NS1-lipoprotein complexes provide enhanced diagnostic and prognostic value, allowing for early detection and monitoring of dengue infection severity, potentially reducing mortality rates by improving clinical management.
Implementation Method 1
The nonstructural protein 1 (NS1) participates to viral replication in DENV-infected cells and can be shed in large amounts in the bloodstream of patients experiencing the various clinical grades of dengue disease. NS1 was shown to bind complement and coagulation factors
Data Source
AI summary
The invention concerns methods for early detection, monitoring and prognosis of a flavivirus-induced infection, comprising the detection of a complex formed by the flavivirus non-structural glycoprotein NS1 and plasma lipoprotein particles in a biological anti-NS1 Mab sample during the clinical phase of the infection.